The overall goal of this application is for Farber/Partners Cancer Care (DF/PCC) to serve as a Lead Academic Participating Site in NCTN and become a leading contributor to NCTN activities. DF/PCC is a joint venture focused on conducting clinical trials and clinical investigator training by across three Harvard- affiliate institutions: Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Massachusetts General Hospital. All are national leaders in cancer clinical research and work cohesively through a well- established unified clinical trials program.
Specific aims are: provide leaders to develop and conduct clinical trials, and support NCTN through substantial, robust accrual. While DF/PCC will have as its primary affiliation the Alliance Network Group, faculties will continue their strong historical relationships with a variety of Network Groups. Through a multiple PD/PI model, an engaged interdisciplinary faculty, and a strong operational infrastructure, DF/PCC will provide senior scientific input to trial development trials; identify novel trials to be brought to NCTN; prioritize NCTN trials within our clinical trials portfolio; assure timely activation; provid training and mentoring; distribute funding fairly; and ensure adherence at participating sites. DF/PCC will impact NCTN, which will define new standards of care for adult patients with cancer through 1) scientific leadership in the Steering Committees; 2) participation in CIRB; 3) executive and committee leadership and membership; 4) executive and committee leadership, as well as committee membership; 5) serving as affiliated PIs; 6) leadership in accrual; and 7) training a new generation to participate in the national clinical trials network enterprise.
NCTN trials will be developed and supported by national experts from DF/PCC. We will conduct those trials with greatest potential value in advancing our knowledge and ability to treat cancer. Importantly, trials will be for both common cancers and rare ones that require support from many centers to have a sufficient subject. The benefit to society could be substantial if trials improve survival and quality of life.
Showing the most recent 10 out of 174 publications
